Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$79.04 USD

79.04
596,788

-0.16 (-0.20%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $79.01 -0.03 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Three Reasons to Add Ecolab (ECL) Stock to Your Portfolio

by Zacks Equity Research

Ecolab's (ECL) focus on R&D raises optimism about the stock.

Urmimala Biswas headshot

3 Amazing Health Service Stocks to Brave "Labordemic" in 2024

by Urmimala Biswas

Here are the three stocks, MEDP, ELV and HQY, which have the potential to shield your portfolio from the impact of healthcare staffing challenges in 2024.

3 Reasons to Retain Nevro (NVRO) in Your Portfolio for Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.

5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024

by Zacks Equity Research

Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.

McKesson (MCK) Announces Availability of PNH's FDA-Approved Drug

by Zacks Equity Research

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PNH.

Three Reasons to Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

Here's Why You Should Retain Veeva Systems (VEEV) Stock Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

QuidelOrtho's (QDEL) Latest FDA Nod to Boost Diagnostic Testing

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of the FDA's latest approval is likely to improve clinical care, provide cost savings and deliver sample-to-result molecular testing across all laboratory settings.

Reasons to Add Integer Holdings (ITGR) to Your Portfolio Now

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Veeva Systems (VEEV) Vault Quality Offerings Adopted by Recipharm

by Zacks Equity Research

Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid Recipharm in boosting its operational efficiencies.

3 Reasons to Add HealthEquity (HQY) Stock to Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment

by Zacks Equity Research

The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.

DexCom's (DXCM) G7 CGM Connects With Tandem's Insulin Pump

by Zacks Equity Research

Dexcom's (DXCM) G7 integrates with Tandem's t:slim X2, revolutionizing diabetes care. A perfect combination of accuracy and innovation, this synergy sets a new standard in continuous glucose monitoring.

Molina (MOH) to Pay Lower Price for California Medicare Buyout

by Zacks Equity Research

Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.

Here's Why You Should Retain QuidelOrtho (QDEL) Stock for Now

by Zacks Equity Research

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.

Here's Why Investors Should Hold Elevance (ELV) Stock for Now

by Zacks Equity Research

Elevance's (ELV) Carelon unit will see growth due to improving performance in post-acute care services and Behavioral Health business.

Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Reasons to Retain Baxter International (BAX) in Your Portfolio

by Zacks Equity Research

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.